Colin Goudelocke, MD
Urology · New Orleans, LANPI 1164631149
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,850 of the $123,691 with a category attached, or 72.6%. Medtronic accounts for 98.4% of it on its own, with 15 other manufacturers making up the rest. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $477.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$122K
- Boston Scientific$416
- Coloplast$388
- Avation Medical, Inc.$176
- Kerecis Limited$172
- Urovant Sciences Inc$150
- plus $648 from 10 others
Across 118 payments — averaging $4275.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$476K
- Ironwood Pharmaceuticals, Inc$28K
What the payments were for
- Consulting fees$8,6697%
- Speaking & faculty fees$89,85073%
- Travel & lodging$17,12614%
- Food & beverage$7,9746%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 224 | $121,743 |
| Boston Scientific | 7 | $416 |
| Coloplast | 5 | $388 |
| Avation Medical, Inc. | 2 | $176 |
| Kerecis Limited | 1 | $172 |
| Urovant Sciences Inc | 1 | $150 |
| KARL Storz Endoscopy-america | 1 | $150 |
| AbbVie(2 entities) | 5 | $145 |
| Sumitomo Pharma America, Inc. | 2 | $139 |
| Viewray Technologies Inc | 3 | $67 |
| Urogen Pharma, Inc. | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 2 | $24 |
| Therapeuticsmd, Inc. | 1 | $24 |
| Pfizer | 1 | $21 |
| Coopersurgical, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$100,214
- ALTAVIVA$10,226
- INTELLIS ADAPTIVESTIM$849
- Kerecis SurgiClose$687
- NURO$350
- GEMTESA$268
- TITAN$268
- AMS 700$260
- Kerecis GraftGuide$172
- Vivally$169
- N/A$150
- INTERSTIM ICON$114
- ICONSYNC$105
How this compares
$123,691 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 753 | $491,392 |
| GemtesaVibegron | 304 | $217,556 |
| Mirabegron ErMirabegron | 22 | $12,293 |
| Solifenacin Succinate | 323 | $9,956 |
| Estradiol | 118 | $8,206 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 44 | $4,612 |
| Methenamine Hippurate | 42 | $3,249 |
| Trimethoprim | 34 | $2,948 |
| Oxybutynin Chloride ErOxybutynin Chloride | 146 | $2,314 |
| Trospium Chloride | 42 | $2,168 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 98 | $1,240 |
| Desmopressin Acetate | 17 | $1,050 |
| Tamsulosin Hcl | 86 | $757 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $459 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 127 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $13 | $491,392753 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $139 | $217,556304 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.